Published in Cancer Invest on June 01, 2009
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer (2009) 1.44
Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion. J Exp Clin Cancer Res (2010) 1.28
Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One (2011) 1.27
Detection and quantification of methylation in DNA using solid-state nanopores. Sci Rep (2013) 1.19
Ecrg4 expression and its product augurin in the choroid plexus: impact on fetal brain development, cerebrospinal fluid homeostasis and neuroprogenitor cell response to CNS injury. Fluids Barriers CNS (2011) 1.16
GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer. J Urol (2014) 1.12
A novel tumor suppressor gene ECRG4 interacts directly with TMPRSS11A (ECRG1) to inhibit cancer cell growth in esophageal carcinoma. BMC Cancer (2011) 1.10
Processing of proaugurin is required to suppress proliferation of tumor cell lines. Mol Endocrinol (2011) 1.06
Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One (2013) 1.05
Oxidative stress and DNA methylation in prostate cancer. Obstet Gynecol Int (2010) 1.03
Esophageal cancer related gene-4 is a choroid plexus-derived injury response gene: evidence for a biphasic response in early and late brain injury. PLoS One (2011) 1.02
ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck in vitro and in vivo. Oncol Lett (2013) 1.01
Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer. Mol Cancer Res (2011) 1.00
Promoter hypermethylation in prostate cancer. Cancer Control (2010) 0.99
Cell surface localization and release of the candidate tumor suppressor Ecrg4 from polymorphonuclear cells and monocytes activate macrophages. J Leukoc Biol (2012) 0.99
C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics (2013) 0.98
Methylation of the SLC6a2 gene promoter in major depression and panic disorder. PLoS One (2013) 0.96
Down-regulation of Filamin A interacting protein 1-like Is associated with promoter methylation and an invasive phenotype in breast, colon, lung and pancreatic cancers [corrected]. PLoS One (2013) 0.90
Vimentin DNA methylation predicts survival in breast cancer. Breast Cancer Res Treat (2012) 0.89
DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol Biol (2012) 0.88
An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma. PLoS One (2012) 0.88
Filamin C, a dysregulated protein in cancer revealed by label-free quantitative proteomic analyses of human gastric cancer cells. Oncotarget (2015) 0.87
DNA methylation gene-based models indicating independent poor outcome in prostate cancer. BMC Cancer (2014) 0.87
Esophageal cancer-related gene 4 at the interface of injury, inflammation, infection, and malignancy. Gastrointest Cancer (2014) 0.85
Esophageal cancer-related gene-4 (ECRG4) interactions with the innate immunity receptor complex. Inflamm Res (2014) 0.84
Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer. Clin Transl Sci (2012) 0.84
Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation. Neuro Oncol (2014) 0.83
Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry. PLoS One (2013) 0.83
Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation. J Mol Diagn (2010) 0.83
Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma. PLoS One (2012) 0.83
Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer. PLoS One (2013) 0.80
Pulmonary preconditioning, injury, and inflammation modulate expression of the candidate tumor suppressor gene ECRG4 in lung. Exp Lung Res (2014) 0.80
PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer. Clin Exp Metastasis (2013) 0.80
Eagles report: Developing cancer biomarkers from genome-wide DNA methylation analyses. World J Clin Oncol (2011) 0.80
Epigenetics in breast and prostate cancer. Methods Mol Biol (2015) 0.79
Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. Int J Cancer (2016) 0.78
A preliminary study of the effect of ECRG4 overexpression on the proliferation and apoptosis of human laryngeal cancer cells and the underlying mechanisms. Mol Med Rep (2015) 0.77
Proteomic analysis of patient tissue reveals PSA protein in the stroma of benign prostatic hyperplasia. Prostate (2014) 0.77
Embryonal Fyn-associated substrate (EFS) and CASS4: The lesser-known CAS protein family members. Gene (2015) 0.76
ECRG4 expression in normal rat tissues: expression study and literature review. Eur J Histochem (2015) 0.76
Clustering-Based Method for Developing a Genomic Copy Number Alteration Signature for Predicting the Metastatic Potential of Prostate Cancer. J Probab Stat (2012) 0.76
Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling. Oncoimmunology (2016) 0.75
Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biol (2016) 0.75
A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer. Oncotarget (2017) 0.75
The epigenomics of cancer. Cell (2007) 30.91
Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32
CpG islands in vertebrate genomes. J Mol Biol (1987) 23.16
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
MethPrimer: designing primers for methylation PCRs. Bioinformatics (2002) 14.48
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
The power and the promise of DNA methylation markers. Nat Rev Cancer (2003) 9.32
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol (2004) 6.99
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Simultaneous gene clustering and subset selection for sample classification via MDL. Bioinformatics (2003) 4.74
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol (2002) 3.06
Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res (2003) 2.91
A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology (2003) 1.84
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol (2008) 1.73
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol (2001) 1.72
Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol (2004) 1.72
Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst (2006) 1.70
GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol (2001) 1.60
Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res (2005) 1.46
Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol (2008) 1.44
Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res (2000) 1.40
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol (2005) 1.38
Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol (2003) 1.37
DNA methyltransferase inhibitors for cancer therapy. Cancer J (2007) 1.37
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res (2005) 1.30
Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev (2006) 1.28
Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys (2008) 1.27
Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res (2006) 1.21
Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res (2005) 1.18
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology (2001) 1.16
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res (2006) 1.13
Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol (2006) 1.07
Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys (1996) 1.06
Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol (2006) 1.03
Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol (2007) 1.02
Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol (2004) 1.01
Dot far-western blot analysis of relative binding affinities of the Src homology 3 domains of Efs and its related proteins. Anal Biochem (1998) 1.00
The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. Rev Urol (2007) 0.92
Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol Appl Pharmacol (2004) 0.90
Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer (2004) 0.87
[GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer]. Urologe A (2004) 0.84
Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker? Clin Chim Acta (2004) 0.81
New markers may help predict prostate cancer relapse risk. JAMA (2006) 0.80
Retinoic acid receptor beta2 hypermethylation: implications for prostate cancer detection, prevention, and therapy. Clin Cancer Res (2004) 0.78
Noise in eukaryotic gene expression. Nature (2003) 13.01
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A (2005) 8.10
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Oct4-induced pluripotency in adult neural stem cells. Cell (2009) 6.50
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Dynamic FoxO transcription factors. J Cell Sci (2007) 6.30
Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A (2008) 5.94
Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med (2010) 5.54
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Prediction and measurement of an autoregulatory genetic module. Proc Natl Acad Sci U S A (2003) 5.07
Engineered riboregulators enable post-transcriptional control of gene expression. Nat Biotechnol (2004) 5.07
DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med (2011) 4.98
Phenotypic consequences of promoter-mediated transcriptional noise. Mol Cell (2006) 4.93
Programmable cells: interfacing natural and engineered gene networks. Proc Natl Acad Sci U S A (2004) 4.72
Mechanisms of androgen-refractory prostate cancer. N Engl J Med (2004) 4.49
Comparative genome sequencing of Escherichia coli allows observation of bacterial evolution on a laboratory timescale. Nat Genet (2006) 4.44
Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol (2011) 4.18
A bottom-up approach to gene regulation. Nature (2006) 4.03
Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol (2004) 3.92
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50
Bacterial charity work leads to population-wide resistance. Nature (2010) 3.50
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science (2006) 3.41
Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat Med (2007) 3.34
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res (2002) 3.26
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med (2012) 3.18
USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 3.17
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A (2005) 3.16
Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad Sci U S A (2007) 3.13
The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11
The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol (2010) 3.08
The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol (2002) 3.08
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol (2011) 2.99
Whole-genome annotation by using evidence integration in functional-linkage networks. Proc Natl Acad Sci U S A (2004) 2.93
Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res (2003) 2.91
A tunable genetic switch based on RNAi and repressor proteins for regulating gene expression in mammalian cells. Cell (2007) 2.83
Association testing by DNA pooling: an effective initial screen. Proc Natl Acad Sci U S A (2002) 2.79
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer (2014) 2.77
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol (2008) 2.68
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol (2010) 2.60
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol (2007) 2.53
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol (2009) 2.37
Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev (2007) 2.34
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol (2011) 2.33
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol (2011) 2.29
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19
A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS. Proc Natl Acad Sci U S A (2003) 2.19
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol (2011) 2.11
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest (2009) 2.09
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol (2013) 2.05
The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc (2012) 2.00
The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int (2004) 2.00
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol (2013) 1.99
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
RNA visualization in live bacterial cells using fluorescent protein complementation. Nat Methods (2007) 1.92
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem (2008) 1.87
The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood (2007) 1.84
Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol (2003) 1.82
Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol (2002) 1.82
Molecular regulation of androgen action in prostate cancer. J Cell Biochem (2006) 1.81
Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol (2003) 1.81
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol (2005) 1.80
Automated genotyping using the DNA MassArray technology. Methods Mol Biol (2002) 1.77
Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol (2010) 1.76
Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol (2012) 1.75
Direct molecular haplotyping of long-range genomic DNA with M1-PCR. Proc Natl Acad Sci U S A (2003) 1.74
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol (2008) 1.73
Outcomes following partial nephrectomy by tumor size. J Urol (2008) 1.72
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer (2005) 1.71
Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy. J Urol (2011) 1.69
Tracking, tuning, and terminating microbial physiology using synthetic riboregulators. Proc Natl Acad Sci U S A (2010) 1.66
MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) (2010) 1.64
Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. Proc Natl Acad Sci U S A (2008) 1.64
General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res (2010) 1.64